Tenaya Therapeutics (TNYA) Operating Leases (2021 - 2026)

Tenaya Therapeutics has reported Operating Leases for 6 years, with the latest figure at $7.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 30.79% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.0 million (down 30.79% YoY), and the FY2025 full-year result was $7.8 million, down 27.89% from the prior year.
• Operating Leases for Q1 2026 stood at $7.0 million, down from $7.8 million in the prior quarter.
• The five-year high for Operating Leases was $13.1 million in Q2 2022, with the low at $7.0 million in Q1 2026.
• Average Operating Leases over 5 years is $10.1 million, with a median of $10.1 million recorded in 2025.
• Year-over-year, Operating Leases soared 38.55% in 2025 and tumbled 30.79% in 2026.
• Tracing TNYA's Operating Leases over 5 years: stood at $11.1 million in 2022, then decreased by 26.94% to $8.1 million in 2023, then jumped by 33.62% to $10.8 million in 2024, then dropped by 27.89% to $7.8 million in 2025, then decreased by 10.35% to $7.0 million in 2026.
• The last three Operating Leases figures came in at $7.0 million (Q1 2026), $7.8 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.

Peer Comparison